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ABSTRACT We present a case of a 5-year-old child with epidermoly-
sis bullosa acquisita, clinically resembling linear IgA bullous disease. 
The case demonstrates that autoimmune bullous dermatoses in child-
hood may show a clinical overlap, which makes the diagnosis based 
on clinical features highly unreliable. Specific immunofluorescence and 
immunoserological tests are crucial for precise diagnosis – in our case 
circulating antibodies against collagen VII were detected using ELISA 
and indirect immunofluorescence on transfected cells. The disease was 
treated with systemic and topical steroids with excellent results.
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INTRODUCTION
Autoimmune bullous dermatoses (AIBDs) in child-
hood show a significant clinical overlap, which makes 
the diagnosis based on clinical features highly unre-
liable. Immunofluorescence and immunoserology 
tests to determine autoantibody specificity are there-
fore essential in establishing the correct diagnosis. 
Epidermolysis bullosa acquisita (EBA) is an ac-
quired autoimmune bullous dermatosis character-
ized by subepidermal bullae formation, mediated by 
autoantibodies against type VII collagen (Col VII). EBA 
is very rare in childhood and can exhibit variable clini-
cal phenotypes, mimicking other AIBDs such as linear 
IgA dermatosis (LAD)(1-3), bullous pemphigoid (BP) 
(4), or even mucous membrane pemphigoid (MMP) 
(5). The unlikelihood of EBA in childhood makes the 
clinical diagnosis in such cases almost impossible.
CASE REPORT
A 5-year-old girl presented with a pruritic blister-
ing eruption lasting 2 months that had not respond-
ed to previous therapy with antiviral and antibiotic 
agents. No trigger of the condition could be identi-
fied. She was otherwise healthy and had not been 
on any medications prior to the onset of the skin dis-
ease.
Physical examination revealed widespread poly-
morphic vesiculo-bullous lesions forming plaques 
with an annular, concentric, and serpiginous pattern 
of distribution over the face, trunk, and extremities 
(Figure 1). The blisters ruptured, leaving behind ero-
sions and crusts. There was no mucosal involvement. 
Based on the patient’s age and the clinical picture 
with a characteristic “string of pearls” sign, a prelimi-
nary diagnosis of LAD was established.
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Histology of a vesicle showed a subepidermal blis-
ter with dense mixed inflammatory infiltrate in the 
upper dermis. Direct immunofluorescence on perile-
sional skin revealed linear deposits of IgG (+++), IgM 
(+), and C3 (+++) along the basement membrane 
zone (BMZ) (Figure 2). U-serrated pattern of IgG and 
C3 deposition could be observed. The patient’s serum 
was positive for dermal type IgG anti-BMZ antibod-
ies by indirect immunofluorescence on salt-split skin 
substrate (IIF SSS). Circulating antibodies to the non-
collagenous (NC1) domain of type VII collagen were 
detected using ELISA (44 RU/mL; cut-off value 20 
RU/mL) and IIF on transfected cells (BIOCHIP, Euroim-
mun, Medizinische Labordiagnostika AG, Lübeck, 
Germany). ELISA for detecting circulating antibodies 
to BP180 was negative. Based on these findings, the 
diagnosis of EBA was established.
Treatment with oral methylprednisolone at an ini-
tial dose of 12 mg once daily and subsequent reduc-
tion over a period of 3 months, plus topical steroids, 
lead to complete resolution of the eruption with 
transitory milia formation and residual hyperpigmen-
tation. One year later, the child was clinically healthy, 
without any cutaneous or systemic complaints.
DISCUSSION
EBA is a rare condition. The average age of onset 
is around 40 years, and women are more commonly 
affected (6). The condition is even rarer in childhood, 
although several cases have been reported in recent 
years (7-12).
Classical EBA presents with formation of spon-
taneous or trauma-induced non-inflammatory vesi-
culo-bullous skin lesions, which resolve with atrophic 
scars and milia. Skin fragility is a typical feature with 
distribution of the blisters on the extensor surfaces of 
the arms and hands, as well as on the elbows, knees, 
sacrum, and soles of the feet. Childhood EBA can be 
clinically indistinguishable from other subepidermal 
AIBDs, requiring a combination of diagnostic meth-
ods to provide a sensitive and reliable diagnostic al-
gorithm in routine practice.
Direct IF is the “gold standard” test to diagnose 
subepidermal AIBDs by demonstrating linear deposi-
tion of immunoglobulins and C3 at the BMZ. IgA at 
the BMZ is found in LAD, which is the most common 
AIBD in childhood. IgA-mediated EBA has also been 
described in children (5,13), which further highlights 
the need for more specific tests to establish the cor-
rect diagnosis in subepidermal AIBDs. In our case, 
despite the clinical resemblance to LAD, the immu-
nological process was found to be IgG-mediated. 
Deposition of IgG points to a diagnosis of BP or EBA 
without differentiating between the two conditions.
Different immunodeposition patterns have been 
suggested to distinguish collagen type VII target-
ing bullous diseases from other AIBD (14). An n-ser-
rated pattern was found in BP, MMP, anti-laminin 332 
pemphigoid, anti-p200 pemphigoid, and LAD, cor-
responding with depositions located in hemidesmo-
somes, the lamina lucida, or lamina densa. However, 
the u-serrated staining pattern was detected in EBA 
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Figure 1. Widespread polymorphic vesiculo-bullous lesions forming plaques with an annular, concentric, and serpiginous 
pattern of distribution over the face and extremities.
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and bullous systemic lupus erythematosus, corre-
sponding with the ultralocalization of type VII colla-
gen in the sublamina densa zone (14). Nevertheless, 
these patterns are often difficult to interpret and oth-
er methods are needed for more precise diagnosis.
On IIF SSS, patients with EBA demonstrate immune 
deposits on the dermal side of the artificial blister 
(“floor pattern”), whereas the deposits are found on 
the epidermal side (“roof pattern”) in BP and LAD (10). 
This technique, however, does not distinguish EBA 
from other “floor” binding diseases such as anti-p200 
pemphigoid and anti-laminin 332 pemphigoid (10).
A sensitive enzyme-linked immunosorbent as-
say (ELISA) has been developed using recombinant 
proteins to detect autoantibodies against collagen 
VII (15). The main antigen epitopes in EBA are locat-
ed on the non-collagen domain 1 (NC1) of collagen 
VII, but other potential antibody targets have been 
found. ELISA has been accepted as an alternative to 
immunoelectron microscopy in the diagnosis of the 
disease. Despite the high sensitivity of the method, 
most ELISA kits show some limitations in detecting 
antibodies against the NC1 domain of collagen VII, 
which can lead to false negative results when other 
regions of the molecule are targeted.
A new diagnostic method for IIF on Col VII trans-
fected cells is also available. We used both this test 
and ELISA to find circulating anti-collagen VII NC1 an-
tibodies in our patient. 
CONCLUSION
Adult EBA is a chronic condition, and treatment is 
sometimes difficult and disappointing. In more resis-
tant cases, systemic steroids, often in combinations 
with cyclophosphamide, azathioprine, or methotrex-
ate, can have little effect on the condition. Similarly 
to our case, childhood EBA is characterized by better 
overall prognosis and responds well to dapsone or/
and lower doses of prednisolone (3,14).
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